Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
New biotech advancing RNA therapeutics for rare genetic cardiomyopathies. Lead PRKAG2 program is in phase I/II, with proof-of-concept data expected next year, alongside strategic collaborations and a broader pipeline.
Unresolved biotech is advancing RNA therapeutics for rare genetic cardiomyopathies, focusing on PRKAG2 and PLN syndromes. Lead program is in Phase I/II, with proof-of-concept data expected next year and strategic partnerships supporting the pipeline.